U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

OVARIAN CANCER, EPITHELIAL, SOMATIC

MedGen UID:
358303
•Concept ID:
C1868358
•
Finding
OMIM®: 171834

Professional guidelines

PubMed

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K
Expert Opin Investig Drugs 2022 Jun;31(6):607-631. Epub 2022 May 3 doi: 10.1080/13543784.2022.2067527. PMID: 35435784Free PMC Article
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Kurnit KC, Fleming GF, Lengyel E
Obstet Gynecol 2021 Jan 1;137(1):108-121. doi: 10.1097/AOG.0000000000004173. PMID: 33278287Free PMC Article
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
J Clin Oncol 2020 Oct 20;38(30):3468-3493. Epub 2020 Aug 13 doi: 10.1200/JCO.20.01924. PMID: 32790492Free PMC Article

Recent clinical studies

Etiology

Single-cell transcriptomic analysis of endometriosis.
Fonseca MAS, Haro M, Wright KN, Lin X, Abbasi F, Sun J, Hernandez L, Orr NL, Hong J, Choi-Kuaea Y, Maluf HM, Balzer BL, Fishburn A, Hickey R, Cass I, Goodridge HS, Truong M, Wang Y, Pisarska MD, Dinh HQ, El-Naggar A, Huntsman DG, Anglesio MS, Goodman MT, Medeiros F, Siedhoff M, Lawrenson K
Nat Genet 2023 Feb;55(2):255-267. Epub 2023 Jan 9 doi: 10.1038/s41588-022-01254-1. PMID: 36624343Free PMC Article
Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets.
Nameki R, Chang H, Reddy J, Corona RI, Lawrenson K
Pharmacol Ther 2021 Apr;220:107722. Epub 2020 Nov 1 doi: 10.1016/j.pharmthera.2020.107722. PMID: 33137377
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article
Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P, Walentowicz-Sadłecka M, Grabiec M
Ginekol Pol 2017;88(12):692-697. doi: 10.5603/GP.a2017.0123. PMID: 29303228
Rare non-epithelial ovarian neoplasms: Pathology, genetics and treatment.
Foulkes WD, Gore M, McCluggage WG
Gynecol Oncol 2016 Jul;142(1):190-198. Epub 2016 Apr 19 doi: 10.1016/j.ygyno.2016.04.005. PMID: 27079213

Diagnosis

Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, Domchek SM, Drapkin R, Shih IM, Brown EJ, Hwang WT, Armstrong DK, Gaillard S, Giuntoli R, Simpkins F
Clin Cancer Res 2023 Aug 1;29(15):2800-2807. doi: 10.1158/1078-0432.CCR-22-2444. PMID: 37097611
Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer.
Wang Y, Xie H, Chang X, Hu W, Li M, Li Y, Liu H, Cheng H, Wang S, Zhou L, Shen D, Dou S, Ma R, Mao Y, Zhu H, Zhang X, Zheng Y, Ye X, Wen L, Kee K, Cui H, Tang F
Cancer Res 2022 Nov 2;82(21):3903-3916. doi: 10.1158/0008-5472.CAN-21-3819. PMID: 35969151Free PMC Article
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.
Paffenholz SV, Salvagno C, Ho YJ, Limjoco M, Baslan T, Tian S, Kulick A, de Stanchina E, Wilkinson JE, Barriga FM, Zamarin D, Cubillos-Ruiz JR, Leibold J, Lowe SW
Proc Natl Acad Sci U S A 2022 Feb 1;119(5) doi: 10.1073/pnas.2117754119. PMID: 35082152Free PMC Article
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
J Clin Oncol 2020 Oct 20;38(30):3468-3493. Epub 2020 Aug 13 doi: 10.1200/JCO.20.01924. PMID: 32790492Free PMC Article
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article

Therapy

Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, Domchek SM, Drapkin R, Shih IM, Brown EJ, Hwang WT, Armstrong DK, Gaillard S, Giuntoli R, Simpkins F
Clin Cancer Res 2023 Aug 1;29(15):2800-2807. doi: 10.1158/1078-0432.CCR-22-2444. PMID: 37097611
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K
Expert Opin Investig Drugs 2022 Jun;31(6):607-631. Epub 2022 May 3 doi: 10.1080/13543784.2022.2067527. PMID: 35435784Free PMC Article
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Kurnit KC, Fleming GF, Lengyel E
Obstet Gynecol 2021 Jan 1;137(1):108-121. doi: 10.1097/AOG.0000000000004173. PMID: 33278287Free PMC Article
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
J Clin Oncol 2020 Oct 20;38(30):3468-3493. Epub 2020 Aug 13 doi: 10.1200/JCO.20.01924. PMID: 32790492Free PMC Article
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article

Prognosis

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K
Expert Opin Investig Drugs 2022 Jun;31(6):607-631. Epub 2022 May 3 doi: 10.1080/13543784.2022.2067527. PMID: 35435784Free PMC Article
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.
Paffenholz SV, Salvagno C, Ho YJ, Limjoco M, Baslan T, Tian S, Kulick A, de Stanchina E, Wilkinson JE, Barriga FM, Zamarin D, Cubillos-Ruiz JR, Leibold J, Lowe SW
Proc Natl Acad Sci U S A 2022 Feb 1;119(5) doi: 10.1073/pnas.2117754119. PMID: 35082152Free PMC Article
A profile on the FoundationFocus CDxBRCA tests.
Ford L, Wolford JE, Brown SM, Randall LM
Expert Rev Mol Diagn 2020 Mar;20(3):285-292. Epub 2020 Feb 6 doi: 10.1080/14737159.2020.1701438. PMID: 32028808
PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
Cook SA, Tinker AV
BioDrugs 2019 Jun;33(3):255-273. doi: 10.1007/s40259-019-00347-4. PMID: 30895466
Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions.
Grisham RN, Iyer G
Curr Treat Options Oncol 2018 Sep 18;19(11):54. doi: 10.1007/s11864-018-0571-8. PMID: 30225651

Clinical prediction guides

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K
Expert Opin Investig Drugs 2022 Jun;31(6):607-631. Epub 2022 May 3 doi: 10.1080/13543784.2022.2067527. PMID: 35435784Free PMC Article
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.
Paffenholz SV, Salvagno C, Ho YJ, Limjoco M, Baslan T, Tian S, Kulick A, de Stanchina E, Wilkinson JE, Barriga FM, Zamarin D, Cubillos-Ruiz JR, Leibold J, Lowe SW
Proc Natl Acad Sci U S A 2022 Feb 1;119(5) doi: 10.1073/pnas.2117754119. PMID: 35082152Free PMC Article
A profile on the FoundationFocus CDxBRCA tests.
Ford L, Wolford JE, Brown SM, Randall LM
Expert Rev Mol Diagn 2020 Mar;20(3):285-292. Epub 2020 Feb 6 doi: 10.1080/14737159.2020.1701438. PMID: 32028808
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article
PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
Cook SA, Tinker AV
BioDrugs 2019 Jun;33(3):255-273. doi: 10.1007/s40259-019-00347-4. PMID: 30895466

Recent systematic reviews

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
J Clin Oncol 2020 Oct 20;38(30):3468-3493. Epub 2020 Aug 13 doi: 10.1200/JCO.20.01924. PMID: 32790492Free PMC Article
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article
The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P
Crit Rev Oncol Hematol 2018 Nov;131:83-89. Epub 2018 Sep 3 doi: 10.1016/j.critrevonc.2018.08.011. PMID: 30293710
Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.
Ciccone MA, Maoz A, Casabar JK, Machida H, Mabuchi S, Matsuo K
Expert Opin Investig Drugs 2016 Jul;25(7):781-96. Epub 2016 May 13 doi: 10.1080/13543784.2016.1181748. PMID: 27101098Free PMC Article
Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis.
Encinas G, Maistro S, Pasini FS, Katayama ML, Brentani MM, Bock GH, Folgueira MA
Rev Assoc Med Bras (1992) 2015 Sep-Oct;61(5):474-83. doi: 10.1590/1806-9282.61.05.474. PMID: 26603012

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...